Phenotypic differences between apolipoprotein E genetic subgroups: research and clinical implications
TL;DR: APOE e4 carriers have a faster rate of cognitive decline both preclinically and during the mild cognitive impairment (MCI) stage, and a higher burden of cerebrovascular amyloid that may be the basis for the observed gene-dose-related increased frequency of immunomodulatory therapy-induced meningoencephalitis and cerebral microhemorrhages.
read more
Abstract: With the recent interest in Alzheimer's disease course modification and earlier, even preclinical, intervention, questions have arisen regarding the potentially confounding impact of apolipoprotein E (APOE) genotype on study design, therapeutic outcomes, and even clinical practice APOE e4 carriers have a faster rate of cognitive decline both preclinically and during the mild cognitive impairment (MCI) stage, and a higher burden of cerebrovascular amyloid that may be the basis for the observed gene-dose-related increased frequency of immunomodulatory therapy-induced meningoencephalitis and cerebral microhemorrhages To date, this has impacted study design in some research trials but not clinical practice
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Clinical symptoms and symptom signatures of Alzheimer's disease subgroups.
TL;DR: Analysis of 196 clinically diagnosed AD or Alzheimer with Lewy body, and 75 non-AD neurological and non-neurological control cases showed that the presence of hallucination, hypokinesia, paranoia, rigidity, or tremors individually could diagnose AD with sensitivities and specificities.
21
Cognitive functions, lipid profile, and Apolipoprotein E gene polymorphism in postmenopausal women.
Iwona Bojar,Jakub Owoc,Alfred Owoc,Angelina Wójcik-Fatla,Grzegorz Raszewski,Jaroslav Stanciak,Dorota Raczkiewicz +6 more
TL;DR: Loss of body weight in postmenopausal women was related with lower results in neurocognitive index and the majority of cognitive functions, and significant differences were observed according to APOE gene polymorphism in correlations between LDL/HDL and CHOL/ HDL ratios, and results in the processing speed and reaction time.
18
Population Difference in the Associations of KLOTH Promoter Methylation with Mild Cognitive Impairment in Xinjiang Uygur and Han Populations.
Mei Luo,Xiaohui Zhou,Huihui Ji,Wenjuan Ma,Guili Liu,Dongjun Dai,Jingyun Li,Lan Chang,Lei Xu,Liting Jiang,Shiwei Duan,Qinwen Wang +11 more
TL;DR: The results showed that KLOTHO promoter hypermethylation contributed to the MCI risk in Xinjiang Han Chinese but not in Beijing Uygur Chinese, and the population difference in the risk of MCI required further investigation in the future.
Postmenopausal cognitive changes and androgen levels in the context of apolipoprotein E polymorphism
Iwona Bojar,Jarosław Pinkas,Mariusz Gujski,Alfred Owoc,Dorota Raczkiewicz,Kasia Gustaw Rothenberg +5 more
TL;DR: Hormonal balance variations after menopause may influence brain processes concerned with cognition, especially memory and psychomotor speed in the changed hormonal dynamics of the postmenopausal period.
Development of a new biochip array for APOE4 classification from plasma samples using immunoassay-based methods.
Sigrun Badrnya,Tara Doherty,Ciaran Richardson,Robert Ivan Mcconnell,John Victor Lamont,Michael Veitinger,Stephen Peter Fitzgerald,Maria Zellner,Ellen Umlauf +8 more
TL;DR: The biochip’s potential for being incorporated in quantitative protein biomarker arrays capable of analyzing disease stages makes it a superior alternative to PCR-based APOE genotyping and may deliver additional protein-specific information on a variety of diseases in the future.
4
References
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
Elizabeth H. Corder,Ann M. Saunders,Warren J. Strittmatter,Donald E. Schmechel,P. C. Gaskell,Gary W. Small,A. D. Roses,Jonathan L. Haines,Margaret A. Pericak-Vance +8 more
TL;DR: The APOE-epsilon 4 allele is associated with the common late onset familial and sporadic forms of Alzheimer9s disease (AD) in 42 families with late onset AD.
9.6K
Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
Clive Holmes,Clive Holmes,Delphine Boche,David Wilkinson,David Wilkinson,Ghasem Yadegarfar,Ghasem Yadegarfar,Vivienne Hopkins,Antony James Bayer,Roy W. Jones,Roger Bullock,Seth Love,James Neal,Elina Zotova,James A. R. Nicoll +14 more
TL;DR: Although immunisation with Abeta(42) resulted in clearance of amyloid plaques in patients with Alzheimer's disease, this clearance did not prevent progressive neurodegeneration and there was no evidence of improved survival.
1.5K
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.
Jean-Marc Orgogozo,Sid Gilman,Jean-François Dartigues,Bernard Laurent,Michèle Puel,L. C. Kirby,Pierre Jouanny,Bruno Dubois,L. Eisner,S. Flitman,Bernard Michel,Mercè Boada,Ana Frank,C. Hock +13 more
TL;DR: Postvaccination meningoencephalitis occurred without clear relation to serum anti-Aβ42 antibody titers and potential mechanisms such as T-cell and microglial activation may be responsible and are under consideration to develop a safer anti- Aβ immunotherapy for AD.
1.4K
Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.
Melissa E. Murray,Neill R. Graff-Radford,Owen A. Ross,Ronald C. Petersen,Ranjan Duara,Dennis W. Dickson +5 more
TL;DR: H hippocampal sparing and limbic-predominant AD subtypes might account for about 25% of cases, and hence should be considered when designing clinical, genetic, biomarker, and treatment studies in patients with AD, and support the hypothesis that AD has distinct clinicopathological subtypes.
C-11-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Juha O. Rinne,David J. Brooks,Martin N. Rossor,Nick C. Fox,Roger Bullock,William E. Klunk,Chester A. Mathis,Kaj Blennow,Jerome Barakos,A Okello,Sofia Rodriguez Martinez de Liano,Enchi Liu,Martin Koller,Gregg Keith M,Dale Schenk,Ronald Black,Michael Grundman +16 more
TL;DR: Treatment with bapineuzumab for 78 weeks reduced cortical (11)C-PiB retention compared with both baseline and placebo and seems to be useful in assessing the effects of potential Alzheimer's disease treatments on cortical fibrillar amyloid-beta load in vivo.
743